38 results about "Treatment medication" patented technology

This invention provides a highly pathogenic feline calicivirus strain, its vaccine, and its applications. The highly pathogenic feline calicivirus was isolated from pathogenic material and identified as a highly pathogenic strain, named FCV CC475, with its cDNA sequence shown in SEQ ID NO.1. This strain exhibits strong pathogenicity, causing infected animals to develop symptoms such as fever, paw pad ulcers, and dehydration by day 3 post-infection; the viral load after 5 generations is 10. 9.80 TCID 50 / ml. This strain produces high antibody titers after immunization of cats and rabbits, demonstrating good immunogenicity. Therefore, this highly pathogenic feline calicivirus has broad application prospects in the preparation of feline calicivirus infection vaccines, diagnostic reagents, or therapeutic drugs.

The present invention is directed to an antioxidant ophthalmic emulsion. More particularly, the present invention is directed to an ophthalmic emulsion having a unique combination of ingredients that promotes the transparent property of small oil droplets within the emulsion and promotes the therapeutic delivery capability of the emulsion.

This invention discloses a wearable ultrasound delivery device for treating otitis media, comprising a wearable main body with a flexible structure adapted to the shape of the patient's ear canal, and a through-hole central channel; an ultrasound drug delivery device, detachably disposed within the central channel, comprising a drug carrier for carrying the therapeutic drug to be delivered, an ultrasound transducer assembly for providing an ultrasound-guided drug delivery mode, and a handheld controller for adjusting the millimeter-level displacement of the drug carrier into the middle ear cavity; wherein, the ultrasound transducer assembly comprises a flexible substrate and multiple piezoelectric transducer units integrated on the flexible substrate, the multiple piezoelectric transducer units constituting a phased array transducer array. This device solves the technical problems of inaccurate drug delivery, low drug delivery efficiency, inability to adapt to the ear canal structure, and complex operation in the prior art.

The application discloses a kind of self-assembly hydrogel, preparation method and application, belong to material field.The application claims to protect a kind of self-assembly hydrogel, it is formed by glycyrrhizic acid, five gallate glucose and paeonol by molecular self-assembly;Wherein, the mass ratio of glycyrrhizic acid and five gallate glucose, paeonol is (10~60) :(1~8) :(2~8).The self-assembly hydrogel provided by the application is suitable for skin, raw material is natural, biocompatibility is good, mechanical and storage stability is excellent, can release paeonol and the transdermal effect is good, three components synergistically improve atopic dermatitis and other skin inflammation, and clinical value is high.In addition, the preparation process of the self-assembly hydrogel of the application is simple, can be prepared using conventional one-pot method, easy to produce.Therefore, the self-assembly hydrogel of the application has the prospect of developing into paeonol sustained-release delivery system, paeonol transdermal sustained-release preparation or skin inflammation treatment drug.

This invention discloses a cation-cavity-dynamic covalent nanonetwork functional synergistic microring, its preparation method, and its application, belonging to the field of biomedical materials. The microring has an anisotropic ring structure with a positively charged inner wall and an environmentally responsive polyphenolic dynamic covalent nanonetwork grafted onto the outer wall. The inner wall enables electrostatic capture and physical confinement of bacteria, while the outer wall enables broad-spectrum adhesion and antibacterial effects, synergistically achieving integrated functions of capture, antibacterial, and anti-inflammatory. The preparation method uses polystyrene (PS) microspheres as seeds to obtain a Patchy template, which is then coated with silica, amino-functionalized, grafted with a dynamic covalent nanonetwork, and the template is removed and purified to obtain the target microring. The process is mild, the structure is uniform, and the biocompatibility is excellent. The microring of this invention has high capture and bactericidal efficiency against common clinical pathogens and significant antioxidant and anti-inflammatory effects. It can be used in the research and development of drugs for the treatment of bacterial infection-related inflammatory diseases, providing a novel carrier and technical direction for antibacterial and anti-infective biomedical materials.

Systems, devices, and methods for treating drug-refractory epilepsy are disclosed. [Solution] In one embodiment, a method for treating epilepsy is disclosed, comprising detecting electrophysiological signals of a subject using a first electrode array coupled to a first intravascular carrier. The method further comprises analyzing the electrophysiological signals using a neuromodulator electrically coupled to the first electrode array, and stimulating a target site in the subject's body using a second electrode array coupled to a second intravascular carrier implanted in a portion of a body blood vessel above the base of the subject's skull.

This application provides a screening method and animal model related to intraocular diseases, such as age-related macular degeneration (AMD), for identifying candidate therapeutic agents for treating or preventing eye diseases, such as AMD. [Solution] The present application also provides compounds / compositions that can kill or inhibit the growth of microorganisms such as Bacillus megatherium. The present application further provides methods for treating infections caused by microorganisms such as Bacillus megatherium, and for treating or preventing diseases or disorders associated with such infections, such as AMD, using the compounds / compositions.

This invention discloses a method for extracting and preparing polysaccharides from the traditional Chinese medicine *Cat Ginseng* and its applications. The process involves drying and pulverizing the raw material, defatting it with 95% ethanol, and then using ultrasound-assisted extraction. The liquid-to-solid ratio, extraction time, and ultrasonic power are optimized using response surface methodology. The extract is then centrifuged, concentrated, precipitated with alcohol, deproteinized and decolorized using macroporous resin, dialyzed, and freeze-dried to obtain crude polysaccharides. These crude polysaccharides are then purified by DEAE-52 and Sephadex G-150 column chromatography to obtain three homogeneous new polysaccharide fractions: AvPs1-1, AvPs2-1, and AvPs2-2. The polysaccharide extract, dominated by AvPs2-1 and AvPs2-2, not only exhibits protective effects on zebrafish embryonic development but also demonstrates significant anti-fibrotic activity in a liver injury model. Due to its natural non-toxicity, water solubility, and multiple functions including embryonic development protection and anti-fibrosis, this polysaccharide shows broad application prospects in functional foods, health products, and therapeutic drugs.

The application discloses an ex vivo heart perfusion system and a perfusion control method, wherein the perfusion system comprises: an organ bin, which is externally provided with a constant temperature heating film for controlling the temperature in the organ bin to be a first preset temperature threshold; a liquid storage container for containing a perfusion medium, an outlet end of the liquid storage container being connected to a first active branch vein through a first liquid supply pipe and connected to a pulmonary vein through a second liquid supply pipe, an inlet end of the liquid storage container being connected to a second active branch vein through a first liquid return pipe and connected to a pulmonary artery through a second liquid return pipe; a circulating pump connected to the first liquid supply pipe; an oxygenator connected to the first liquid supply pipe, the oxygenator being connected with a gas supply module for adjusting the gas mixing ratio in the perfusion medium; and an injection pump group for supplementing injection of nutrient substances or therapeutic drugs. The application can effectively prolong the heart supply storage time, reduce the heart supply discard rate, and further improve the utilization rate of the heart supply.

In accordance with the inventive concepts, provided is a cryo-delivery apparatus and method. In various embodiments, the cryo-delivery apparatus is useful to perform a percutaneous cryo-delivery method. In one embodiment, a therapeutic is adhered by freezing to a distal end of a catheter, the distal end is brought into contact with tissue to be treated, e.g., directed percutaneously, and the distal end is then thawed to deliver the therapeutic to the tissue. In another embodiment, the distal end is directed to the tissue to be treated, e.g., percutaneously, then brought to freezing to established stable coupling to the tissue, a therapeutic is then directed through the catheter and distal end to the treatment site, the distal end is thawed to release and deliver the therapeutic to the tissue, and the catheter can then be withdrawn.

Infusion tubing has an upstream segment upstream of a pump and a downstream segment downstream of the pump. A side-tube filled with air has a proximal end in fluid communication with the downstream segment and a sealed distal end. When pressure in the downstream segment increases, therapeutic substance enters the side-tube, thereby compressing the air and reducing the pressure within the downstream segment. When the pressure in the downstream segment decreases, the compressed air pushes the therapeutic substance back into the downstream segment. An inner diameter of the side-tube is sufficiently small such that in the absence of positive pressure within the downstream segment, surface tension at the proximal end of the side-tube prevents the therapeutic substance from flowing into the side-tube regardless of the orientation of the side-tube with respect to gravity. Other applications are also described.

This application relates to a method for preparing magnetically responsive drug-loaded microspheres based on a high-throughput microfluidic chip in the field of biomedical microsphere preparation technology. The method involves encapsulating carboxylated magnetic nanoparticles via suspension polymerization, then co-forming them with biodegradable polymers and therapeutic drugs to create a magnetically responsive dispersed phase. Through structural design, multiple microsphere generation units are integrated on a single chip, arranged concentrically, to achieve one-step high-throughput generation of monodisperse oil-in-water emulsion droplets. Subsequent processing yields magnetically responsive drug-loaded microspheres with uniform particle size distribution and tunable saturation magnetization. This invention overcomes the problems of easy magnetic core aggregation, poor microsphere particle size uniformity, low throughput of traditional microfluidic preparation, and complex integration of magnetic response and drug-loading functions in existing technologies. It is suitable for various biomedical applications such as targeted chemotherapy, drug sustained release, magnetothermal synergistic therapy, and nucleic acid / protein delivery, and has advantages such as rapid and scalable preparation process, high batch stability, and precise magnetic field control.

The invention belongs to the technical field of cellular neurobiology, and relates to a method for capturing a dynamic interaction group of fusion protein and intracellular amyloid protein and application of the method. In the capturing method, the fusion protein is formed by fusing tandem repeat amyloid protein and proximity marker enzyme through flexible connecting peptide; through the design of the tandem repeat sequence of the amyloid A beta, the flexible connecting peptide, the proximity marker enzyme and the like, the local multivalence of the protein is remarkably improved, the saturation concentration required by phase separation is further reduced exponentially, more and more lasting liquid condensates can be stably formed in cells, and the phase separation efficiency is improved. Thus, the metastable oligomer droplets formed by the liquid aggregate are stabilized under physiological conditions. Fluorescence bleaching recovery verifies that the agglomerate generated by the method has pathological liquid-solid phase change characteristics (no fluorescence recovery), and successfully simulates the aging process of amyloid protein. The invention provides a powerful tool for researching a phase separation mediated pathogenic mechanism in amyloid protein related neurodegenerative diseases (such as Alzheimer's disease) and screening a therapeutic drug for agglutinate aging or protein hijacking.

A thermally balanced filler bone graft scaffold includes a scaffold shell and a base. The scaffold shell has an inner cavity. The base has a multi-purpose chamber at its tail end and a heat convection tube assembly at its head end. The multi-purpose chamber is connected to the surface of the head end of the base via the heat convection tube assembly. The heat convection tube assembly connects the inner cavity of the scaffold shell with the multi-purpose chamber of the base. This provides a stable support base, promotes the bone integration process, achieves thermal balance of the overall scaffold, appropriately increases the internal temperature of the femoral head, accelerates local blood circulation in the femoral head, enhances cell activity, accelerates metabolism, promotes the proliferation and differentiation of osteocytes and other related cells, promotes angiogenesis and bone repair, facilitates gas exchange, promotes the drainage of effusion and gas, continuously releases intraosseous pressure, and provides storage space and pathways for therapeutic drugs and / or nutrients. This implant achieves multi-system synergy and promotes overall rehabilitation.

An mRNA pharmaceutical composition for preventing and treating tuberculosis and use thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable excipient. The Mycobacterium tuberculosis antigen comprises the following antigen components: at least one Mycobacterium tuberculosis early-secreted antigen or an immunologically active fragment thereof; at least one Mycobacterium tuberculosis PE / PPE family antigen or an immunologically active fragment thereof; and at least one Mycobacterium tuberculosis latency-associated antigen or an immunologically active fragment thereof. The mRNA pharmaceutical composition does not comprise or further comprises an mRNA molecule encoding a cytokine. The pharmaceutical composition is used for preparing a tuberculosis vaccine, which can be used not only as a prophylactic vaccine for preventing latency activation, but also as a therapeutic drug for treating active tuberculosis, and has a significant inhibitory effect on Mycobacterium tuberculosis.

Microparticles that contain miRNA that controls the production of nitric oxide and are an agent for promoting the production of nitric oxide are new microparticles that enable controlling the expression of a protein and / or a gene related to erectile dysfunction; a preventive drug or a therapeutic drug for erectile dysfunction; a method for improving erectile dysfunction; it is preferable that the microparticles be exosomes; and it is preferable that the microparticles of the present disclosure contain miRNA targeting a gene concerning the expression of nitric oxide synthase as the miRNA that controls the production of nitric oxide, and be an agent for promoting the expression of nitric oxide synthase.

The invention relates to the field of medical apparatus and instruments, in particular to a hand support type catheter pushing robot which comprises a first shell, an arc-shaped seat, a first outer box, a bidirectional driving assembly and a second shell. The device not only has basic pushing and withdrawing functions of a catheter and a guide wire, but also integrates an intermittent rotating assembly and an auxiliary injection assembly. And the intermittent rotation function simulates the twisting action of a doctor during manual operation. And the auxiliary injection assembly can automatically or semi-automatically inject a contrast agent or a therapeutic drug after the catheter is in place, so that the combination of diagnosis and treatment functions is realized.

This invention discloses a cerebral vascular targeted therapy and neuromodulation system based on magnetically controlled microcapsules, belonging to the field of medical device and neuromodulation technology. The system includes a magnetic navigation device, an alternating magnetic field generator, microcapsules, and a delivery catheter. The shell of the microcapsule is made of biodegradable hydrogel, internally loaded with magnetic nanoparticles and therapeutic drugs, and optionally, a contrast agent. The microcapsule is released into the vicinity of a targeted intracranial blood vessel through the delivery catheter. Under the combined action of a static magnetic field and a gradient magnetic field, the microcapsule navigates and positions itself within complex and tortuous small blood vessels. Subsequently, the alternating magnetic field drives the microcapsule to generate mechanical vibration or rotation, enhancing the contact and diffusion of local drugs with thrombi or lesions, improving the treatment efficiency for distal small vessel thrombosis, local infections, or tumors. When close to a specific brain region, the magnetomechanical or magnetothermal effects of the microcapsule can also provide controllable stimulation to local neurons, achieving high spatial resolution neuromodulation. Compared with traditional mechanical thrombectomy, systemic thrombolysis, and transcranial magnetic / electrical stimulation, this invention improves targeting and spatial accuracy while ensuring minimally invasiveness and reducing the risk of systemic side effects.

This invention discloses a traditional Chinese medicine composition for treating wind-heat type common cold and its preparation method, relating to the field of traditional Chinese medicine technology. The composition is made from the following raw materials in parts by weight: 15-20 parts of *Ilex asprella*, 10-15 parts of mulberry leaf, 4-10 parts of wild chrysanthemum, 4-10 parts of *Viola yedoensis*, 10-15 parts of *Senecio scandens*, and 4-10 parts of dandelion. The preparation method includes: mixing the raw materials, soaking in 6-10 times the amount of water for 15-60 minutes; decocting twice, maintaining the boil for 1.5-2 hours each time, filtering and combining the filtrates; concentrating to a relative density of 1.14-1.18 at 80°C, cooling, adding 95% ethanol to achieve an alcohol content of 65-70%, stirring and standing for 12-24 hours, collecting the supernatant; recovering the ethanol under reduced pressure to obtain an extract and concentrating to a relative density of 1.25-1.30 at 80°C. This invention solves the problems of existing drugs for treating wind-heat colds having a narrow range of indications, insufficient extraction of effective components or incomplete removal of impurities in the preparation process, and the need to improve product quality stability.

The application discloses a kind of targeting cat calicivirus VP1-CDE protein chicken source single-chain antibody and its preparation and application, belong to biotechnology field.The single-chain antibody is selected from X2B2, X2E1 Or X2G5, its heavy chain variable region and light chain variable region amino acid sequence are respectively as shown in SEQ ID NO:1-6.The application is prokaryotic expression and purified VP1-CDE protein as antigen immunization chicken, amplifies VH And VL Gene and is spliced into scFv gene by (Gly4Ser) 3 linker, constructs library capacity not less than 5.25×10 7 CFU / mL phage display library, specific single-chain antibody clone is obtained by solid-phase panning, and its binding activity is verified by Western blot, ELISA, indirect immunofluorescence test after eukaryotic expression and purification.The results show that the three single-chain antibodies can specifically bind VP1-CDE protein and FCV virus particles, and there is no cross reaction, which provides key experimental materials for basic research of cat calicivirus, can be used for developing FCV rapid diagnostic reagent or kit, also provides candidate molecules for the development of FCV infection treatment drugs, and has important theoretical significance and application value.

The application relates to the technical field of medicines, in particular to application of a VER155008 compound in preparation of a coronavirus-dependent RNA polymerase antagonist. Through construction of a reliable screening model of SARS-CoV-2 RdRp inhibitors, the application tests the inhibiting effect of a plurality of nucleoside analogs on SARS-CoV-2 RdRp, finds that the VER155008 compound has obvious inhibiting effect on SARS-CoV-2 RdRp, the VER155008 compound has SARS-CoV-2 exonuclease nsp14 resistance, and can effectively inhibit replication of coronaviruses HCoV-OC43 and HCoV-NL63. Therefore, the application provides key data for research and development of a novel anti-new coronavirus lead compound, and provides a theoretical basis for research and development of an effective coronavirus treatment drug.

The application relates to application of ginkgo biloba lactone A in preparation of drugs against white spot syndrome, aiming at the problem that effective treatment drugs are still lacking for the destructive damage of white spot syndrome virus (WSSV) to aquatic crustaceans, and providing a new application of ginkgo biloba lactone A; through in-vitro experiment of Hpt cells of astacus leptodactylus and in-vivo feeding experiment of astacus leptodactylus, it is verified that the ginkgo biloba lactone A can significantly inhibit WSSV replication at a concentration of 100 muM; the astacus leptodactylus is fed with 40 mg / kg feed for 10 days, the survival rate after being infected with WSSV is increased by about 53.3%, meanwhile, the expression of immune-related genes is up-regulated, the apoptosis rate of blood cells is reduced, and the virus replication is significantly inhibited; a safe and efficient new drug for the prevention and control of WSSV in aquatic breeding is provided, and has important industrial application value.

The present invention provides a pharmaceutical composition for use in therapy or prevention of the novel coronavirus (SARS-CoV-2) disease 2019 (COVID-19), the composition containing an IL-10 inhibitor.

An apparatus for controlling a driver for a mist inhalation pod for delivering a mist including a therapeutic. The apparatus comprises a main printed circuit board (PCB) and a controller mounted to the main PCB, the controller including a processor and a memory, the memory storing executable instructions which, when executed by the processor, control at least one function of the apparatus. The apparatus comprises a load driver circuit mounted to the main PCB, the load driver circuit being configured to generate a load drive signal to control generation of the mist in the mist inhalation pod, the mist including the therapeutic. The apparatus comprises a fuel gauge circuit configured to monitor the charge level of a battery. The apparatus further comprises first and second switches that are controllable by the controller to electrically connect / disconnect the load driver circuit and the fuel gauge circuit to the battery. The load driver circuit and the fuel gauge circuit are disconnected when the load driver circuit and the fuel gauge circuit are not in use to minimise power consumption by the battery.

The application provides a construction method and application of a polycystic ovary syndrome animal model; through a way of intragastric administration, the mouse intestinal tract is transplanted with fusobacterium nucleatum, and through a certain frequency, the fusobacterium nucleatum can be stably planted, and a stable polycystic ovary syndrome symptom is successfully generated; the sex hormone level of the mouse is significantly different from the PCOS characteristic, is shown as the increase of the LH level, the LH / FSH ratio and the T level, and multiple vesicle structures are seen in the ovary, and no mature follicle and corpus luteum are seen, so that the typical symptom of the polycystic ovary syndrome is met, and a new model selection is provided for screening of a treatment drug or experimental research of the polycystic ovary syndrome.

The application discloses a microsporum gene deletion strain of Cryptosporidium parvum with deleted DG9 and / or DG10 genes and application thereof. The microsporum gene deletion strain of Cryptosporidium parvum is obtained by directly knocking out dense granule protein DG9 genes and / or DG10 genes of Cryptosporidium parvum through a gene editing technology. The application discloses the regulation of Cryptosporidium parvum dense granule proteins DG9 and DG10 on the pathogenicity of Cryptosporidium parvum. Research shows that the strain with deleted DG9 or DG10 genes or double gene deletion can reduce the clinical symptoms of infected mice and prolong the survival time of the mice. The virulence of the gene deletion strain is weakened, the worm load in the mice is reduced, and the excretion intensity of oocysts is weakened, so that the gene deletion strain has the advantage of weakened virulence and can be used for developing more attenuated vaccines and therapeutic drugs of Cryptosporidium parvum, thereby laying a solid foundation for the prevention and control of Cryptosporidium parvum.

The invention relates to an ophthalmic liposomal formulation for topical use that improves paracellular penetration of therapeutic agents such as aflibercept in the eyeball. The formulation includes an optimised mixture of liposomes, non-ionic solubilisers and excipients to facilitate the transport of the drug through the cornea and the controlled release thereof in the posterior segment of the eye. The formulation uses liposomes as a transport system, maximising the ocular bioavailability of aflibercept by means of a synergic combination of emulsifiers and stabilisers, allowing efficient penetration through the corneal barrier and sustained release of the drug in the eye tissue.